Clinical Trial Update: Effect of Maridebart Cafraglutide on the Heart's Electrical Activity [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial sponsored by Amgen is evaluating Maridebart Cafraglutide for overweight/obesity and monitoring its effects on the heart's electrical ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Maridebart Cafraglutide

Snippet

Sponsor: Amgen | Conditions: Overweight, Obesity | Phase 1 | Status: ACTIVE_NOT_RECRUITING